A Dose-ranging, Safety, and Efficacy Trial with Zafirlukast (ACCOLATE) in the Treatment of Pediatric Subjects with Mild-to-moderate Asthma; up to a 52-week Open-label Safety Extension (9188IL/0139). Report for the Open-label Extension only.
Study identifier:9188IL/0139
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Dose-ranging, Safety, and Efficacy Trial with Zafirlukast (ACCOLATE) in the Treatment of Pediatric Subjects with Mild-to-moderate Asthma; up to a 52-week Open-label Safety Extension (9188IL/0139). Report for the Open-label Extension only.
Medical condition
asthma
Phase
Phase 3
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Feb 1997
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
